![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
(MM) | NASDAQ:IDIX | NASDAQ | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.50 | 0.00 | 01:00:00 |
*
|
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
CUSIP No. 45166R 20 4
|
|
|
|
|
1
|
|
NAMES OF REPORTING PERSONS
MERCK & CO., INC.
|
||||||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
ý
(b)
o
|
||||||||
3
|
|
SEC USE ONLY
|
||||||||
4
|
|
SOURCE OF FUNDS
N/A
|
||||||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e):
o
|
||||||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
NEW JERSEY
|
||||||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
0
|
||||||
|
8
|
|
SHARED VOTING POWER
22,477,560
(1)
|
|||||||
|
9
|
|
SOLE DISPOSITIVE POWER
0
|
|||||||
|
10
|
|
SHARED DISPOSITIVE POWER
0
|
|||||||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
22,477,560
(1)
|
||||||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
ý
|
||||||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14.9%
(1)
|
||||||||
14
|
|
TYPE OF REPORTING PERSON
CO
|
(1)
|
An aggregate of 22,477,560 shares of common stock, par value $0.001 per share, of Idenix Pharmaceuticals, Inc. (the “Issuer”) are subject to a Support Agreement dated June 8, 2014 (the “Support Agreement”), entered into by Merck & Co., Inc. (“Parent”), Imperial Blue Corporation (“Merger Sub”), a wholly-owned subsidiary of Parent, and The Baupost Group, L.L.C. (the “Stockholder”). Parent and Merger Sub expressly disclaim beneficial ownership of any shares of Issuer common stock subject to the Support Agreement. Based on 150,856,104 shares of Issuer common stock outstanding as of the close of business on June 8, 2014 (as represented by the Issuer in the Merger Agreement, discussed in Items 3 and 4 of this Schedule 13D), the aggregate number of shares of Issuer common stock subject to the Support Agreement represents approximately 14.9 % of the Issuer’s outstanding common stock as of the close of business on June 8, 2014.
|
CUSIP No. 45166R 20 4
|
|
|
|
|
1
|
|
NAMES OF REPORTING PERSONS
IMPERIAL BLUE CORPORATION
|
||||||||
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
ý
(b)
o
|
||||||||
3
|
|
SEC USE ONLY
|
||||||||
4
|
|
SOURCE OF FUNDS
N/A
|
||||||||
5
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e):
o
|
||||||||
6
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
|
||||||||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH:
|
|
7
|
|
SOLE VOTING POWER
0
|
||||||
|
8
|
|
SHARED VOTING POWER
22,477,560
(1)
|
|||||||
|
9
|
|
SOLE DISPOSITIVE POWER
0
|
|||||||
|
10
|
|
SHARED DISPOSITIVE POWER
0
|
|||||||
11
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
22,477,560
(1)
|
||||||||
12
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
ý
|
||||||||
13
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14.9%
(1)
|
||||||||
14
|
|
TYPE OF REPORTING PERSON
CO
|
(1)
|
An aggregate of 22,477,560 shares of common stock, par value $0.001 per share, of the Issuer are subject to the Support Agreement. Parent and Merger Sub expressly disclaim beneficial ownership of any shares of Issuer common stock subject to the Support Agreement. Based on 150,856,104 shares of Issuer common stock outstanding as of the close of business on June 8, 2014 (as represented by the Issuer in the Merger Agreement, discussed in Items 3 and 4 of this Schedule 13D), the aggregate number of shares of Issuer common stock subject to the Support Agreement represents approximately 14.9 % of the Issuer’s outstanding common stock as of the close of business on June 8, 2014.
|
2.1
|
Agreement and Plan of Merger, dated as of June 8, 2014, by and among the Issuer, Parent and Merger Sub (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Issuer with the SEC on June 9, 2014).
|
2.2
|
Form of Support Agreement (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer with the SEC on June 9, 2014).
|
99.1
|
Joint Filing Agreement, dated as of June 13, 2014, by and between Parent and Merger Sub.
|
Date: June 13, 2014
|
MERCK & CO., INC.
|
|
|
/s/ Katie E. Fedosz
|
|
|
Name:
|
Katie E. Fedosz
|
|
Title:
|
Senior Assistant Secretary
|
|
IMPERIAL BLUE CORPORATION
|
|
|
/s/ Sunil A. Patel
|
|
|
Name:
|
Sunil A. Patel
|
|
Title:
|
Vice President
|
Name
|
Age
|
Position
|
|
|
|
Kenneth C. Frazier
|
59
|
Chairman, President and Chief Executive Officer; Director
|
Leslie A. Brun
|
61
|
Director
|
Thomas R. Cech
|
66
|
Director
|
Thomas H. Glocer
|
54
|
Director
|
William B. Harrison, Jr.
|
70
|
Director
|
C. Robert Kidder
|
69
|
Director
|
Rochelle B. Lazarus
|
66
|
Director
|
Carlos E. Represas*
|
68
|
Director
|
Patricia F. Russo
|
61
|
Director
|
Craig B. Thompson
|
61
|
Director
|
Wendell P. Weeks
|
54
|
Director
|
Peter C. Wendell
|
63
|
Director
|
|
|
|
|
|
|
Adele D. Ambrose
|
57
|
Senior Vice President and Chief Communications Officer
|
Robert M. Davis
|
48
|
Executive Vice President and Chief Financial Officer
|
Willie A. Deese
|
58
|
Executive Vice President and President, Merck Manufacturing Division
|
Richard R. Deluca, Jr.
|
51
|
Executive Vice President and President, Merck Animal Health
|
Clark Golestani
|
47
|
Executive Vice President and Chief Information Officer
|
Mirian M. Graddick-Weir
|
59
|
Executive Vice President, Human Resources
|
Bridgette P. Heller
|
52
|
Executive Vice President and President, Merck Consumer Care
|
Michael J. Holston
|
51
|
Executive Vice President and Chief Ethics and Compliance Officer
|
Rita A. Karachun
|
50
|
Senior Vice President Finance-Global Controller
|
Bruce N. Kuhlik
|
57
|
Executive Vice President and General Counsel
|
Roger M. Perlmutter
|
61
|
Executive Vice President and President, Merck Research Laboratories
|
Michael Rosenblatt
|
66
|
Executive Vice President and Chief Medical Officer
|
Adam H. Schechter
|
49
|
Executive Vice President and President, Global Human Health
|
|
|
|
* Citizen of Spain and Mexico
|
|
|
Name
|
Age
|
Position
|
|
|
|
Sunil A. Patel
|
43
|
Director, Vice President
|
Lawrence D. Senour
|
49
|
Director
|
|
|
|
Robert M. Davis
|
48
|
Chief Executive Officer
|
Bruce N. Kuhlik
|
57
|
Vice President
|
Deepa Talpade
|
44
|
Secretary
|
|
|
|
1 Year (MM) Chart |
1 Month (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions